- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04671251
Phase 1b Study of AEVI-007 in Subjects With Relapsed or Refractory Multiple Myeloma
A Multicenter, Open-Label, Dose-Escalation Phase 1b Study of AEVI-007 in Subjects With Relapsed or Refractory Multiple Myeloma
This is a multicenter, open-label, dose-escalation Phase 1b study of AEVI-007 in subjects with relapsed or refractory Multiple Myeloma.
The objectives of the study are to evaluate the safety, pharmacokinetics and pharmacodynamics of AEVI-007.
Study Overview
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
California
-
Sacramento, California, United States, 95817
- University of California, Davis Comprehensive Cancer Center
-
West Hollywood, California, United States, 90069
- James R. Berenson, MD., Inc.
-
-
Florida
-
Lake Mary, Florida, United States, 32746
- Florida Cancer Specialists
-
Sarasota, Florida, United States, 34232
- Florida Cancer Specialists
-
-
Maryland
-
Bethesda, Maryland, United States, 20817
- American Oncology Partners of Maryland, PA
-
-
North Carolina
-
Charlotte, North Carolina, United States, 28204
- Levine Cancer Institute
-
-
Wisconsin
-
Milwaukee, Wisconsin, United States, 53226
- Froedtert Hospital & the Medical College of Wisconsin
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Subject has active R/R multiple myeloma.
Subject has measurable myeloma based on any of the following:
- Serum M-protein > 0.5 g/dL
- Urine M-protein > 200 mg/24 hours
- Serum free light chains > 10 mg/dL
- Measurable plasmacytoma or extramedullary disease
Subject has active myeloma despite prior therapy with a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 antibody.
Note: Subject must not be a candidate for regimens known to provide clinical benefit.
- Subject has an Eastern Cooperative Oncology Group performance status (ECOG PS) score of 0 or 1.
- Subject is > 18 years of age.
Subject has adequate hematopoietic, renal and hepatic function, defined as:
- Absolute neutrophil count > 1,000/μL; platelet count > 75,000/μL in patients with < 50% marrow involvement
- Absolute neutrophil count > 750/μL; platelet count > 50,000/μL in patients with >50% marrow involvement
- Serum creatinine < 2.5 mg/dL or calculated creatinine clearance of > 30 mL/min according to the Cockcroft-Gault equation
- Aspartate transaminase/alanine transaminase ≤2.5× the upper limit of normal (ULN) and total bilirubin < 2× the ULN
- If applicable, the subject has undergone prior autologous hematopoietic stem cell transplantation more than 100 days prior to the Screening Visit.
- Female patients of childbearing potential who are heterosexually active and male patients with female sexual partners of childbearing potential must agree to use an effective method of contraception (eg, oral contraceptives, double-barrier methods such as a condom and a diaphragm, intrauterine device) or abstain from sexual activity during the study and for 220 days (5 half-lives) following the last dose of study medication, or to abstain from sexual intercourse for this duration of study participation. A woman not of childbearing potential is one who has undergone bilateral oophorectomies or who is post-menopausal, defined as the absence of menstrual periods for 12 consecutive months.
- Subject has provided written informed consent for this study.
Exclusion Criteria:
- Subject has currently active infection requiring use of systemic antimicrobial therapy.
- Subject has received corticosteroids (>10 mg/daily prednisone or equivalent) or chemotherapy within 2 weeks of study drugs (4 weeks for nitrosourea, melphalan or monoclonal antibodies).
- Subject has hyperviscosity syndrome.
- Subject has central nervous system involvement by myeloma, including leptomeningeal involvement.
- Subject is judged to be at risk for impending fracture.
- Subject has known amyloidosis or POEMS (Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal protein, Skin changes) syndrome.
- Subject had another malignancy within 1 year of study entry with high probability of recurrence.
- Subject is pregnant or lactating.
- Subject has a history of, or tests positive for, hepatitis B, untreated hepatitis C or human immunodeficiency virus (HIV). Subject with hepatitis C who has received a full course of anti-viral therapy or who is currently receiving anti-viral therapy with undetectable levels of hepatitis C RNA is eligible for the trial.
- Subject has undergone major surgery or trauma within 4 weeks of study entry.
- Subject has been previously treated with an anti IL 18 antibody.
- Subject is currently taking immunomodulatory drugs, including pharmacologic doses of systemic glucocorticoids (> 10 mg prednisone daily or equivalent), anti tumor necrosis factor alpha (TNFα) antibodies, anti-IL-17 antibodies, anti IL 12/23 antibodies, phosphodiesterase-4 (PDE-4) inhibitors, janus kinase (JAK) inhibitors, IL-6 inhibitors, rituximab, methotrexate, cyclosporine, mycophenolate.
- Subject with known active autoimmune disorders including, but not limited to, rheumatoid arthritis, lupus, systemic sclerosis, Sjogren's syndrome, psoriatic arthritis, ulcerative colitis, Crohn's disease, vasculitis, multiple sclerosis. Subjects with autoimmune endocrinopathies on stable doses of replacement hormone therapy are eligible for the trial.
- Subject has had a prior allogeneic transplant.
- Subject has New York Heart Association (NYHA) Class III or IV Congestive Heart Failure (CHF), myocardial infarction or acute coronary syndrome within 6 months prior to the Screening Visit, ongoing angina pectoris, severe peripheral vascular disease, or any other concomitant medical disorder that might interfere with the subject's participation in the trial or interpretation of the study data.
- Subject has psychiatric, substance abuse or social conditions that would interfere with the subject's participation or cooperation with the requirements of the trial.
- Subject has known hypersensitivity to any of the components of AEVI-007.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: AEVI-007
Open-label, dose-escalation, single-arm
|
50 mg of AEVI-007 and will be reconstituted with 1.2 mL of water for injection.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Recommended Phase 2 Dose
Time Frame: Cohorts 1-3 will take approximately 4-5 months
|
Identify the recommended Phase 2 dose based on safety, pharmacokinetics and pharmacodynamics observed in this Phase 1b study.
|
Cohorts 1-3 will take approximately 4-5 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of Treatment Emergent Adverse Events (TEAEs)
Time Frame: Approximately 9 months
|
Approximately 9 months
|
|
Incidence of Clinically Significant Changes in Clinical Laboratory Results
Time Frame: Approximately 9 months
|
Approximately 9 months
|
|
Incidence of Clinically Significant Changes in Vital Signs
Time Frame: Approximately 9 months
|
Approximately 9 months
|
|
Incidence of Clinically Significant Changes in Electrocardiogram Recordings
Time Frame: Approximately 9 months
|
Approximately 9 months
|
|
Incidence of Clinically Significant Changes to Eastern Cooperative Oncology Group Performance Status (ECOG PS) Score
Time Frame: Approximately 9 months
|
Approximately 9 months
|
|
Incidence of Clinically Significant Changes in Physical Examination Findings
Time Frame: Approximately 9 months
|
Approximately 9 months
|
|
Maximum Observed Concentration of AEVI-007
Time Frame: Approximately 9 months
|
Approximately 9 months
|
|
Apparent Terminal Half-Life of AEVI-007
Time Frame: Approximately 9 months
|
Approximately 9 months
|
|
Clearance of AEVI-007
Time Frame: Approximately 9 months
|
Approximately 9 months
|
|
Volume of Distribution of AEVI-007
Time Frame: Approximately 9 months
|
Approximately 9 months
|
|
Area Under the Concentration-Time Curve From Time 0 to Time t of AEVI-007
Time Frame: Approximately 9 months
|
Approximately 9 months
|
|
Anti-myeloma activity
Time Frame: Approximately 9 months
|
To assess the anti-myeloma activity of AEVI-007 based on International Myeloma Working Group (IMWG) criteria for response
|
Approximately 9 months
|
Determination of ADAs
Time Frame: Approximately 9 months
|
To determine the incidence of anti-drug antibodies to AEVI-007.
|
Approximately 9 months
|
Time to Response (TTR)
Time Frame: Approximately 9 months
|
Defined as the time from start of the treatment to the first observation of PR or better.
TTR is restricted to only subjects with confirmed responses.
|
Approximately 9 months
|
Progression Free Survival (PFS)
Time Frame: Approximately 9 months
|
Defined as the duration from start of the treatment to disease progression or death (regardless of cause of death), whichever comes first
|
Approximately 9 months
|
Duration of Response
Time Frame: Approximately 9 months
|
Defined as the duration from the first observation of PR to the time of disease progression, with deaths from causes other than progression censored
|
Approximately 9 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Manish Patel, MD, Florida Cancer Specialist
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Immunoproliferative Disorders
- Hematologic Diseases
- Hemorrhagic Disorders
- Hemostatic Disorders
- Paraproteinemias
- Blood Protein Disorders
- Multiple Myeloma
- Neoplasms, Plasma Cell
Other Study ID Numbers
- AEVI-007-MM-101
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Myeloma
-
Lawson Health Research InstituteThe Ottawa Hospital; Hamilton Health Sciences Corporation; Dalhousie University; Niagara Health SystemActive, not recruitingMultiple Myeloma in Relapse | Multiple Myeloma With Failed Remission | Multiple Myeloma Stage I | Multiple Myeloma Progression | Multiple Myeloma Stage II | Multiple Myeloma Stage IIICanada
-
National Cancer Institute (NCI)Active, not recruitingSmoldering Multiple Myeloma | Refractory Multiple Myeloma | DS Stage I Multiple Myeloma | DS Stage II Multiple Myeloma | DS Stage III Multiple MyelomaUnited States
-
Fred Hutchinson Cancer Research Center/University...National Cancer Institute (NCI)CompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)TerminatedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
Mayo ClinicCompletedMultiple Myeloma | Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
National Cancer Institute (NCI)TerminatedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
National Cancer Institute (NCI)CompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
City of Hope Medical CenterCompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
University of WashingtonNational Cancer Institute (NCI)TerminatedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
Clinical Trials on AEVI-007
-
Apollo Therapeutics LtdTerminatedAdult Onset Still's DiseaseUnited States, Belgium, Poland, Ukraine
-
Aevi Genomic Medicine, LLC, a Cerecor companyCompletedAttention Deficit Hyperactivity DisorderUnited States
-
Aevi Genomic Medicine, LLC, a Cerecor companyCompletedAttention Deficit Hyperactivity DisorderUnited States
-
Aevi Genomic Medicine, LLC, a Cerecor companyCompletedAcute Lung Injury | ARDS | COVID-19 PneumoniaUnited States
-
Dr. August Wolff GmbH & Co. KG ArzneimittelParexelCompletedDermatitis, AtopicGermany
-
Avalo Therapeutics, Inc.CompletedNon-Eosinophilic AsthmaUnited States
-
Qilu Pharmaceutical Co., Ltd.Unknown
-
Avalo Therapeutics, Inc.TerminatedCrohn Disease | Ulcerative ColitisUnited States
-
Suzhou Yabao Pharmaceutical R&D Co., Ltd.Suspended
-
Recognify Life SciencesCompletedSchizophrenia | Cognitive ImpairmentUnited States